Published in Euro Surveill on December 15, 2004
PATRIC: the VBI PathoSystems Resource Integration Center. Nucleic Acids Res (2006) 3.06
In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob (2006) 1.12
Brucellosis: the case for live, attenuated vaccines. Vaccine (2009) 1.12
Laboratory animal models for brucellosis research. J Biomed Biotechnol (2011) 1.05
Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infect Immun (2007) 0.96
Epidemiological features and risk factors associated with the spatial and temporal distribution of human brucellosis in China. BMC Infect Dis (2013) 0.94
Pathophysiology of the rhesus macaque model for inhalational brucellosis. Infect Immun (2011) 0.90
CD80/CD28 co-stimulation in human brucellosis. Clin Exp Immunol (2006) 0.85
Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice. Infect Immun (2011) 0.84
Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approach. PLoS One (2013) 0.83
Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis. Front Cell Infect Microbiol (2013) 0.82
Contrasting Lifestyles Within the Host Cell. Microbiol Spectr (2016) 0.77
Effect of carbon dioxide on broth microdilution susceptibility testing of Brucella spp. J Clin Microbiol (2009) 0.75
The pathophysiology of inhalational brucellosis in BALB/c mice. Sci Rep (2012) 0.75
Closure of schools during an influenza pandemic. Lancet Infect Dis (2009) 6.68
Malaria risk in travelers. Emerg Infect Dis (2005) 1.87
The dioxin crisis as experiment to determine poultry-related campylobacter enteritis. Emerg Infect Dis (2002) 1.65
Outbreak of West Nile virus infection in Greece, 2010. Emerg Infect Dis (2011) 1.58
The 2000 tularemia outbreak: a case-control study of risk factors in disease-endemic and emergent areas, Sweden. Emerg Infect Dis (2002) 1.58
Bichat clinical guidelines for bioterrorist agents. Euro Surveill (2004) 1.54
Dengue fever in travelers to the tropics, 1998 and 1999. Emerg Infect Dis (2003) 1.50
A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect Dis (2011) 1.42
Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill (2004) 1.29
Malaria in Greece: historical and current reflections on a re-emerging vector borne disease. Travel Med Infect Dis (2013) 1.12
Parents' reported reasons for avoiding MMR vaccination. A telephone survey. Scand J Prim Health Care (2005) 1.11
[Time for booster doses against whooping cough for 10-year-old children]. Lakartidningen (2005) 1.07
Endemic tularemia, Sweden, 2003. Emerg Infect Dis (2005) 0.99
Bichat guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro Surveill (2004) 0.98
Timeliness of MMR vaccination--influence on vaccination coverage. Vaccine (2004) 0.98
Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia. Euro Surveill (2004) 0.97
Dual-use research and technological diffusion: reconsidering the bioterrorism threat spectrum. PLoS Pathog (2011) 0.96
The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine (2008) 0.93
Rickettsioses in Swedish travellers, 1997-2001. Scand J Infect Dis (2003) 0.92
Serologic analysis of returned travelers with fever, Sweden. Emerg Infect Dis (2009) 0.92
Toxicokinetic-toxicodynamic modeling of quantal and graded sublethal endpoints: a brief discussion of concepts. Environ Toxicol Chem (2011) 0.91
Epidemiology of hepatitis C in Belgium: present and future. Acta Gastroenterol Belg (2002) 0.89
Bichat guidelines for the clinical management of plague and bioterrorism-related plague. Euro Surveill (2004) 0.88
Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax. Euro Surveill (2004) 0.87
Mapping environmental suitability for malaria transmission, Greece. Emerg Infect Dis (2013) 0.87
West Nile virus state of the art report of MALWEST Project. Int J Environ Res Public Health (2013) 0.87
Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scand J Infect Dis (2014) 0.86
Bichat guidelines for the clinical management of Q fever and bioterrorism-related Q fever. Euro Surveill (2004) 0.86
Women don't do such things! Characteristics of female sex offenders and offender types. Sex Abuse (2010) 0.83
Travellers returning to Sweden with falciparum malaria: pre-travel advice, behaviour, chemoprophylaxis and diagnostic delay. Scand J Infect Dis (2005) 0.82
Severe degeneration of peripheral motor axons after spinal cord injury: a European multicenter study in 345 patients. Neurorehabil Neural Repair (2010) 0.82
Parents' attitudes towards hepatitis B vaccination for their children. A survey comparing paper and web questionnaires, Sweden 2005. BMC Public Health (2007) 0.82
Moral development and recidivism: a meta-analysis. Int J Offender Ther Comp Criminol (2011) 0.82
A comparison of methods for mammogram registration. IEEE Trans Med Imaging (2003) 0.82
Age structure and senescence in long-term cohorts of Eisenia andrei (Oligochaeta: Lumbricidae). J Gerontol A Biol Sci Med Sci (2007) 0.82
Use of DNA arrays for the analysis of outbreak-related strains of Listeria monocytogenes. Int J Med Microbiol (2006) 0.82
Decreased HIV diversity after allogeneic stem cell transplantation of an HIV-1 infected patient: a case report. Virol J (2010) 0.81
Influenza vaccine coverage and reasons for non-vaccination in a sample of people above 65 years of age, in Sweden, 1998-2000. Scand J Infect Dis (2003) 0.81
Unfinished business: efforts to define dual-use research of bioterrorism concern. Biosecur Bioterror (2011) 0.80
Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012. Vaccine (2013) 0.79
A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. Eur J Epidemiol (2007) 0.79
The European Programme for Intervention Epidemiology Training. Euro Surveill (1996) 0.79
Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism. Euro Surveill (2004) 0.78